It’s important to start prenatal care early – ideally before you even get pregnant – because your health directly affects the health of your baby.
This designation underscores our dedication to caring for people suffering from stroke and supporting their care needs before, during and after a stroke may occur. It is the only hospital in our service area providing 24/7 endovascular care. The hospital-which earned Comprehensive Stroke Center designation from The Joint Commission in July 2018-is home to the region’s only Neuroscience Intensive Care Unit, with 24 beds dedicated to neurosurgical and neuromedicine patients. Vidant Medical Center serves as the regional leader for a stroke system of care, partnering with regional hospitals within the Vidant Health system to optimize care. Vidant Medical Center's neurological surgery department exceeds the national benchmark for the American Heart Association's stroke quality measures. That’s why we continue to be recognized nationally for our patient- and family-centered approach to care, and why we’re the ultimate regional resource for comprehensive health services and clinical expertise. Putting patients first is more than a goal here - it’s a way of life. We’re equally proud of the thousands of dedicated health care professionals who are part of the Vidant team and include specialists from all over the country and around the world.Įvery day, we work to improve patient outcomes through groundbreaking research, innovative technologies and award-winning programs and services at our state-of-the-art facilities. We are proud of the dedicated nurses who care for eastern North Carolina and the patients and families we serve. Learn more about our Magnet® recognition here. We are a tertiary care referral center and in 2018, achieved Magnet® recognition for the second time, designated by the American Nurses Credentialing Center. Vidant Medical Center serves as the flagship teaching hospital for the Brody School of Medicine at East Carolina University. We have 974 licensed beds and are proud to offer extensive inpatient and outpatient services to more than 1.4 million people across 29 counties. Will “watch-and-wait” patients have a different response to the vaccine? Will there be a meaningful difference in seroconversion in patients receiving BTKi vs venetoclax? Should patients be strategically vaccinated prior to initiation of therapy, and if so, how much earlier? In patients with stable disease, is it reasonable to hold the CLL treatment temporarily to allow for an antibody response to the vaccine? If so, what is a reasonable duration for holding? Is there a significant advantage (or disadvantage) of a time-limited therapy before vaccination? What is the impact of previous treatment with monoclonal antibodies or cellular therapy approaches (allogeneic hematopoietic transplant or chimeric antigen receptor T-cell therapy)? More importantly, although timing and quality of a serologic response as a surrogate endpoint are critical, the main question is to understand the clinical impact of vaccination, including level of risk reduction for SARS-CoV-2 infection and identification of possible predictors of such immune response in patients with CLL.Located in Greenville, the fast-growing cultural hub of eastern North Carolina, Vidant Medical Center is the heart of the Vidant Health system. The main emphasis should focus on the impact of CLL-specific treatments. In order to be clinically informative, such a database should include (1) patient characteristics, (2) specifics of the vaccine(s) (type, intensity, frequency), and (3) anti-CLL therapy (see figure). 10 Ideally, we will extend these efforts to a comprehensive vaccine database that will allow for uniform data collection promptly. The CLL research community has already developed a COVID-19/CLL consortium and presented inferior outcomes in this population. Such studies should be planned early to assure inclusiveness, as many patients are expected to receive the vaccine as soon as it becomes available. Therefore, while we await the US Food and Drug Administration’s approval of a SARS-CoV-2 vaccine(s), it is imperative to design studies to assess their efficacy in patients with lymphoid malignancies, including CLL.